Read more

September 03, 2019
1 min read
Save

Glaucoma associated with DSAEK failure

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

COEUR D’ALENE, Idaho — Glaucoma was strongly associated with higher failure rates after Descemet’s stripping automated endothelial keratoplasty, according to a poster presented at the Women in Ophthalmology Summer Symposium.

In a 7-year retrospective chart review, Jefferson Berryman, MD, and colleagues at University of California, Davis, reported an overall failure rate of 17% in 241 eyes that underwent DSAEK performed by a single surgeon; 116 of those eyes were diagnosed previously with glaucoma or ocular hypertension. DSAEK failed in 38 of the glaucomatous eyes (32.8%; P < .0001), whereas only three failures were recorded in eyes without glaucoma (2.4%).

Statistically significantly greater risk for failure was identified in eyes with chronic angle closure (P < .0001), primary open-angle glaucoma (P < .0001) and juvenile open-angle glaucoma (P < .0004).

In eyes that had undergone previous glaucoma surgery, multivariate analysis showed increased risk for failure only in eyes implanted with a glaucoma drainage device.

Twelve eyes required re-bubbling after early graft failure. Postoperative hypotony was found to be the only associated risk factor.

Mean patient age was 68.5 years, mean follow-up was 2.94 years, and mean postoperative best corrected visual acuity was 0.588 logMAR. Patients with follow-up length less than 6 months following surgery were excluded from the analysis.

Regarding medications, “Only beta-blockers were found to increase failure rates for unknown reasons. Other IOP-lowering medication classes had no effect,” the authors wrote. – by Eamon Dreisbach

Reference:

Berryman J, et al. DSAEK survival in eyes with pre-existing glaucoma. Presented at: Women in Ophthalmology Summer Symposium; Aug. 22-25, 2019; Coeur d’Alene, Idaho.

Disclosures: The authors report no relevant financial disclosures.